BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)

Abstract

No AccessJournal of UrologyCLINICAL UROLOGY: Special Communications1 Nov 1999BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS) JOSEPH A. SMITH, RICHARD F. LABASKY, ABRAHAM T.K. COCKETT, JOHN A. FRACCHIA, JAMES E. MONTIE, and RANDALL G. ROWLAND JOSEPH A. SMITHJOSEPH A. SMITH , RICHARD F. LABASKYRICHARD F. LABASKY , ABRAHAM T.K. COCKETTABRAHAM T.K. COCKETT , JOHN A. FRACCHIAJOHN A. FRACCHIA , JAMES E. MONTIEJAMES E. MONTIE , and RANDALL G. ROWLANDRANDALL G. ROWLAND View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68208-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The American Urological Association convened the Bladder Cancer Clinical Guidelines Panel to analyze the literature regarding available methods of treating nonmuscle invasive bladder cancer, and to make practice policy recommendations based primarily on treatment outcomes data. Materials and Methods: The panel searched the MEDLINE database for all articles related to nonmuscle invasive bladder cancer published from 1966 to January 1998. Outcomes data were extracted from articles accepted after panel review and meta-analyzed to produce comparative probability estimates for alternative treatments. Results: All of the intravesical agents (thiotepa, bacillus Calmette-Guerin, mitomycin C and doxorubicin) when used as adjuvant therapy after transurethral resection resulted in a lower probability of recurrence compared to resection alone. However, there is no evidence that intravesical therapy affects long-term progression. Conclusions: For patients with no prior intravesical therapy adjuvant intravesical chemotherapy or immunotherapy is a treatment option after endoscopic removal of low grade Ta bladder cancers. Intravesical instillation of bacillus Calmette-Guerin or mitomycin C is recommended for carcinoma in situ, and after endoscopic removal of T1 and high grade Ta tumors. References 1 Smith, J. A., Labasky, R. F., Cockett, A. T. K., Fracchia, J. A., Montie, J. E. and Rowland, R. G.: Bladder Cancer Clinical Guidelines Panel: Report on the Management of Non-Muscle-Invasive Bladder Cancer (Stages Ta, T1 and Tis). Baltimore: American Urological Association, Inc., 1999. Google Scholar 2 : A Manual for Assessing Health Practices and Designing Practice Policies: the Explicit Approach. Philadelphia: American College of Physicians1992. Google Scholar 3 : The confidence profile method: a Bayesian method for assessing health technologies. Oper. Res.1989; 37: 210. Google Scholar 4 : A Bayesian method for synthesizing evidence: the confidence profile method. Int. J. Technol. Assess. Health Care1990; 6: 31. Google Scholar 5 : FAST*PRO. Software for Meta-Analysis by the Confidence Profile Method. San Diego: Academic Press, Harcourt Brace Jovanovich1992. Google Scholar © 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byBarlow L, McKiernan J and Benson M (2018) Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin TherapyJournal of Urology, VOL. 189, NO. 3, (834-839), Online publication date: 1-Mar-2013.Lu Z, Yeh T, Wang J, Chen L, Lyness G, Xin Y, Wientjes M, Bergdall V, Couto G, Alvarez-Berger F, Kosarek C and Au J (2018) Paclitaxel Gelatin Nanoparticles for Intravesical Bladder Cancer TherapyJournal of Urology, VOL. 185, NO. 4, (1478-1483), Online publication date: 1-Apr-2011.Pruthi R, Baldwin N, Bhalani V and Wallen E (2018) Conservative Management of Low Risk Superficial Bladder TumorsJournal of Urology, VOL. 179, NO. 1, (87-90), Online publication date: 1-Jan-2008.Huang G, Hamilton A, Lo M, Stein J and Penson D (2018) Predictors of Intravesical Therapy for Nonmuscle Invasive Bladder Cancer: Results From the Surveillance, Epidemiology and End Results Program 2003 Patterns of Care ProjectJournal of Urology, VOL. 180, NO. 2, (520-524), Online publication date: 1-Aug-2008.Hall M, Chang S, Dalbagni G, Pruthi R, Seigne J, Skinner E, Wolf J and Schellhammer P (2018) Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, VOL. 178, NO. 6, (2314-2330), Online publication date: 1-Dec-2007.Abaza R, Keck R and Selman S (2018) Intraperitoneal Chemotherapy for the Prevention of Transitional Cell Carcinoma ImplantationJournal of Urology, VOL. 175, NO. 6, (2317-2322), Online publication date: 1-Jun-2006.MULLERAD M, BOCHNER B, ADUSUMILLI P, BHARGAVA A, KIKUCHI E, HUI-NI C, KATTAN M, CHOU T and FONG Y (2018) HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMAJournal of Urology, VOL. 174, NO. 2, (741-746), Online publication date: 1-Aug-2005.MARIAPPAN P and SMITH G (2018) A SURVEILLANCE SCHEDULE FOR G1Ta BLA